Allied Health Software Provider Splose Raises $32M Series A Led by Spectrum Equity

Why It Matters

These capital infusions and regulatory approvals accelerate AI adoption in health‑tech, boosting clinical efficiency, diagnostic reach and patient engagement across the region.

Key Takeaways

• Splose’s Series A funds AI and payment expansion
• Wellumio’s device offers MRI‑like stroke imaging without contrast
• Alcidion’s AI note tool cleared by TGA and MHRA
• NSW tool automates personalized vaccine reminders
• Diabetes Australia backs AI to improve self‑management

Pulse Analysis

The surge of venture capital into health‑technology firms underscores a broader shift toward AI‑enabled care delivery. Splose’s sizable Series A reflects investor confidence that an integrated operating system can streamline scheduling, billing and analytics for thousands of allied‑health practitioners. By embedding predictive algorithms and automated payment gateways, the platform promises to reduce administrative overhead and improve revenue cycle management, positioning it as a competitive alternative to fragmented practice‑management solutions.

AI’s role in diagnostics is gaining regulatory traction, as demonstrated by Wellumio’s portable stroke imaging device and Alcidion’s free‑text note analyzer. Wellumio’s battery‑powered system leverages Pulsed Gradient Free Mapping to generate MRI‑grade biomarkers at the bedside, potentially expanding acute stroke care to settings lacking traditional imaging infrastructure. Meanwhile, Alcidion’s Miya Precision module, now cleared by both the TGA and MHRA, offers clinicians real‑time concept detection and SNOMED‑CT coding suggestions, accelerating documentation while preserving clinical oversight. These approvals signal a maturing ecosystem where AI tools meet stringent safety standards, encouraging broader hospital adoption.

Public‑sector initiatives complement private investment by embedding digital tools into population health strategies. NSW Health’s vaccination scheduler simplifies immunisation planning, using automated calendar reminders to sustain coverage above 90 %. Similarly, Diabetes Australia’s A$2 million AI grant portfolio aims to democratise health‑literacy and empower self‑management, aligning with global trends toward patient‑centric care. Together, these developments illustrate a converging landscape where funding, regulation and government programs collectively drive a more connected, data‑rich healthcare environment.

Deal Summary

Australian allied health software provider splose announced a Series A funding round of A$46 million ($32 million), led by US growth equity firm Spectrum Equity with participation from Athletic Ventures. The capital will be used to expand across Australia and the UK, grow teams in multiple cities, and accelerate AI integration into its practice management platform.